Does high-dose interferon beta-1b improve clinical response in more severely disabled multiple sclerosis patients?

被引：13
作者：
Durelli, L [1 ]
Oggero, A [1 ]
Verdun, E [1 ]
Isoardo, G [1 ]
Ricci, A [1 ]
Barbero, P [1 ]
Bergamasco, B [1 ]
机构：
[1] Univ Turin, Dipartimento Neurosci, Neurol Clin, I-10126 Turin, Italy
来源：
JOURNAL OF THE NEUROLOGICAL SCIENCES | 2000年 / 178卷 / 01期
关键词：
multiple sclerosis; interferon beta; therapy; non-responders; interferon dose;
D O I：
10.1016/S0022-510X(00)00361-0
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Prospective clinical open label follow-up of 52 multiple sclerosis patients treated with interferon beta-lb. After 18 months of treatment at standard 8 million international units (MIU) dose, subcutaneously on alternate days, IFNB dose was increased to 12 MIU in ten clinically non-responder patients. Eighteen months after, mean exacerbation rate, number and severity of exacerbations and number of patients with exacerbations or requiring corticosteroid treatment significantly improved, becoming similar to those of IFNB responders, always treated with 8 MIU. Baseline EDSS score of non-responders was higher than that of responders. Frequency and severity of adverse events were trending higher and dropout frequency higher in 12 MIU IFNB-treated patients. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码：37 / 41
页数：5
相关论文
共 17 条
  • [1] AMASON BG, 1998, J INTERFERON CYTOKIN, V18, P639
  • [2] Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-β1a
    Antonelli, G
    Bagnato, F
    Pozzilli, C
    Simeoni, E
    Bastianelli, S
    Currenti, M
    De Pisa, F
    Fieschi, C
    Gasperini, C
    Salvetti, M
    Dianzani, F
    [J]. JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 1998, 18 (05) : 345 - 350
  • [3] LIMITED DURATION OF THE EFFECT OF METHYLPREDNISOLONE ON CHANGES ON MRI IN MULTIPLE-SCLEROSIS
    BARKHOF, F
    TAS, MW
    FREQUIN, STFM
    SCHELTENS, P
    HOMMES, OR
    NAUTA, JJP
    VALK, J
    [J]. NEURORADIOLOGY, 1994, 36 (05) : 382 - 387
  • [4] Antibodies to beta-interferons in multiple sclerosis - Can we neutralize the controversy?
    Cross, AH
    Antel, JP
    [J]. NEUROLOGY, 1998, 50 (05) : 1206 - 1208
  • [5] INTERFERON BETA-1B IS EFFECTIVE IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS - CLINICAL-RESULTS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    DUQUETTE, P
    GIRARD, M
    DESPAULT, L
    DUBOIS, R
    KNOBLER, RL
    LUBLIN, FD
    KELLEY, L
    FRANCIS, GS
    LAPIERRE, Y
    ANTEL, J
    FREEDMAN, M
    HUM, S
    GREENSTEIN, JI
    MISHRA, B
    MULDOON, J
    WHITAKER, JN
    EVANS, BK
    LAYTON, B
    SIBLEY, WA
    LAGUNA, J
    KRIKAWA, J
    PATY, DW
    OGER, JJ
    KASTRUKOFF, LF
    MOORE, GRW
    HASHIMOTO, SA
    MORRISON, W
    NELSON, J
    GOODIN, DS
    MASSA, SM
    GUTTERIDGE, E
    ARNASON, BGW
    NORONHA, A
    REDER, AT
    MARTIA, R
    EBERS, GC
    RICE, GPA
    LESAUX, J
    JOHNSON, KP
    PANITCH, HS
    BEVER, CT
    CONWAY, K
    WALLENBERG, JC
    BEDELL, L
    VANDENNOORT, S
    WEINSHENKER, B
    WEISS, W
    REINGOLD, S
    PACHNER, A
    TAYLOR, W
    [J]. NEUROLOGY, 1993, 43 (04) : 655 - 661
  • [6] Autoimmune events during interferon beta-1b treatment for multiple sclerosis
    Durelli, L
    Ferrero, B
    Oggero, A
    Verdun, E
    Bongioanni, MR
    Gentile, E
    Isoardo, GL
    Ricci, A
    Rota, E
    Bergamasco, B
    Durazzo, M
    Saracco, G
    Biava, MA
    Brossa, PC
    Giorda, L
    Pagni, R
    Aimo, G
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 1999, 162 (01) : 74 - 83
  • [7] Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis
    Ebers, GC
    Rice, G
    Lesaux, J
    Paty, D
    Oger, J
    Li, DKB
    Beall, S
    Devonshire, V
    Hashimoto, S
    Hooge, J
    Kastrukoff, L
    Krieger, C
    Mezei, M
    Seland, P
    Vorobeychi, G
    Morrison, W
    Nelson, J
    Freedman, MS
    Chrisie, S
    Nelson, R
    Rabinovitch, H
    Freedman, C
    Hartung, HP
    Rieckmann, P
    Archelos, J
    Jung, S
    Weilbach, F
    Flachenecke, P
    Sauer, J
    Hommes, O
    Jongen, P
    Brouwer, S
    McLeod, J
    Pollard, J
    Ng, R
    Sandberg-Wollheim, M
    Källén, K
    Nilsson, P
    Ekberg, R
    Lundgren, A
    Jadbäck, G
    Wikström, J
    Multanen, J
    Valjakka, M
    Carton, H
    Lissoir, F
    Declerq, I
    Vieren, M
    Peeters, E
    Dubois, B
    [J]. LANCET, 1998, 352 (9139) : 1498 - 1504
  • [8] Incidence of exacerbations in the first 90 days of treatment with recombinant human interferon β-1b in patients with relapsing-remitting multiple sclerosis
    Khan, OA
    Hebel, JR
    [J]. ANNALS OF NEUROLOGY, 1998, 44 (01) : 138 - 139
  • [9] SYSTEMIC RECOMBINANT HUMAN INTERFERON-BETA TREATMENT OF RELAPSING-REMITTING MULTIPLE-SCLEROSIS - PILOT-STUDY ANALYSIS AND 6-YEAR FOLLOW-UP
    KNOBLER, RL
    GREENSTEIN, JI
    JOHNSON, KP
    LUBLIN, FD
    PANITCH, HS
    CONWAY, K
    GRANTGORSEN, SV
    MULDOON, J
    MARCUS, SG
    WALLENBERG, JC
    WILLIAMS, GJ
    YOSHIZAWA, CN
    [J]. JOURNAL OF INTERFERON RESEARCH, 1993, 13 (05): : 333 - 340
  • [10] KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444
12